Suchen
Galmed Pharmaceuticals Ltd
GLMDZur Watchlist hinzufügen
0.570USD
-0.079-12.34%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
3.75MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Galmed Pharmaceuticals Ltd Unternehmen
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd Informationen
BörsenkürzelGLMD
Name des UnternehmensGalmed Pharmaceuticals Ltd
IPO-datumMar 13, 2014
CEOBaharaff (Allen)
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeMar 13
Addresse16 Tiomkin Street
StadtTEL AVIV-YAFO
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl6578317
Telefon97236938448
Websitehttps://www.galmedpharma.com
BörsenkürzelGLMD
IPO-datumMar 13, 2014
CEOBaharaff (Allen)
Führungskräfte von Galmed Pharmaceuticals Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
13.96K
+77.62%
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Galmed Pharmaceuticals Ltd?
Die fünf größten Anteilseigner von Galmed Pharmaceuticals Ltd sind: Mr. Allen Baharaff
Wie viele Institutionen halten Anteile an Galmed Pharmaceuticals Ltd (GLMD)?
Mit Stand vom 2026Q1 halten 30 Institutionen Anteile an Galmed Pharmaceuticals Ltd, mit einem Gesamtmarktwert von etwa 224.38K, was 3.40% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 75169.00 gestiegen.